{"slug":"thyroid","tag":"thyroid","variants":["thyroid"],"description":"No description yet","count":11,"kinds":{"person":10,"term":1},"related":[{"slug":"targeted-therapy","tag":"targeted-therapy","shared":5},{"slug":"trialist","tag":"trialist","shared":4},{"slug":"guidelines","tag":"guidelines","shared":2},{"slug":"braf","tag":"braf","shared":1},{"slug":"de-escalation","tag":"de-escalation","shared":1},{"slug":"early-phase","tag":"early-phase","shared":1},{"slug":"neoadjuvant","tag":"neoadjuvant","shared":1},{"slug":"radioiodine","tag":"radioiodine","shared":1},{"slug":"radiotherapy","tag":"radiotherapy","shared":1},{"slug":"rejuvenation","tag":"rejuvenation","shared":1},{"slug":"ret","tag":"ret","shared":1},{"slug":"screening","tag":"screening","shared":1}],"records":[{"id":"lori-wirth","kind":"person","name":"Lori J. Wirth","route":"/people/lori-wirth/","tldr":"Led LIBRETTO-001 in thyroid cancer, which made selpercatinib the first RET-selective drug approved for RET-driven tumours."},{"id":"martin-schlumberger","kind":"person","name":"Martin Schlumberger","route":"/people/martin-schlumberger/","tldr":"Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all."},{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","route":"/people/marcia-brose/","tldr":"Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer."},{"id":"maria-cabanillas","kind":"person","name":"Maria E. Cabanillas","route":"/people/maria-cabanillas/","tldr":"Turned anaplastic thyroid cancer, once measured in months, into a treatable disease with BRAF-targeted therapy and neoadjuvant strategies."},{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","tldr":"Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades."},{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","tldr":"American surgeon who pioneered removing the thyroid in children with inherited RET mutations before cancer develops, led ZETA, the trial that established vandetanib for medullary thyroid cancer, and chaired the American Thyroid Association guideline for the disease."},{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","tldr":"Colorado endocrinologist who chaired the 2015 American Thyroid Association guidelines, the reference for how thyroid nodules and differentiated thyroid cancer are diagnosed and treated."},{"id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","tldr":"Mayo Clinic oncologist who chaired the American Thyroid Association guidelines for anaplastic thyroid cancer, one of the fastest-growing human cancers."},{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","tldr":"Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer."},{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","tldr":"Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials."},{"id":"second-primary-thyroid-after-neck-radiotherapy","kind":"term","name":"Thyroid cancer after neck radiotherapy, and whether to look for it","route":"/terms/second-primary-thyroid-after-neck-radiotherapy/","tldr":"The thyroid is among the most radiation-sensitive tissues there is, and neck or upper chest radiotherapy raises the risk of thyroid cancer for decades. Whether to look for it is genuinely unsettled: the international guideline panel compared ultrasound against feeling the neck, found neither better, and wrote a decision aid instead of a recommendation."}]}